BOSTON, (October 21, 2022)—Caring for patients with monkeypox requires training at scale for caregivers to help limit the spread of the virus. As part of its commitment to provide accessible, accurate health care information, care enablement platform CareAcademy has released a free online resource that educates direct care workers on the monkeypox virus to better care for themselves and their clients during this public health emergency. 

DALLAS (October 20, 2022)—After a thorough audit of its home health, homecare and hospice software solutions, Axxess has earned ACHC Product Certification. The Accreditation Commission for Health Care, Inc. (ACHC) offers product certification based on a comprehensive evaluation of the product’s ability to meet ACHC standards in administration, operations, fiscal management, human resources, provision of care, quality assurance/performance improvement and risk management.
 

CHICAGO (October 20, 2022)—Help at Home, a national provider of in-home, person-centered care for seniors, announced the creation of its new care coordination business segment. Care Coordination from Help at Home will focus on transforming the delivery of in-home personal care services, increasing access to care, improving quality and cost outcomes, and increasing client satisfaction and health equity for aging-in-place seniors, the underserved and chronic care populations.

PHILADELPHIA (October 14, 2022)—Therapy Choice, a Medicare Part B provider that specializes in in-home physical and occupational therapy, has enhanced its personalized home modification program through new partnerships with leading managed care organizations (MCOs). Over the past 20 years, Therapy Choice has been a provider for the Veterans Administration providing veterans with home modification recommendations in Pennsylvania and New Jersey, and now adds MCOs to its resume.

ST. PAUL, Minn. (October 13, 2022)—3M Health Care's Medical Solutions Division announced its 3M V.A.C. Therapy negative pressure wound therapy (NPWT) has surpassed a clinical evidence milestone of 2,000 published, peer-reviewed medical journal studies. V.A.C. Therapy is the first and only NPWT solution to garner this number of published studies about its therapy. It is backed by more clinical data than any other brand, accounting for more than 75% of published NPWT clinical evidence.